A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms

Journal of Investigative Dermatology

Volumn 134, Issue 5, 2014, Pages 1359-1368

  Perez Lorenzo, Rolando ^a   Gill, Kamraan Z ^a   Shen, Che Hung ^b   Zhao, Feng X ^a   Zheng, Bin ^b   Schulze, Hans Joachim ^c   Silvers, David N ^a   Brunner, Georg ^d   Horst, Basil A ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c INST OF REPRO MED OF THE UNIV   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; INOSITOL POLYPHOSPHATE; INOSITOL POLYPHOSPHATE 4 PHOSPHATASE TYPE II; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENES, TUMOR SUPPRESSOR; GTP PHOSPHOHYDROLASES; HUMANS; MCF-7 CELLS; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SKIN NEOPLASMS; TISSUE BANKS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900850019     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.511     Document Type: Article

References (36)

1. Balch C.M. Gershenwald J.E. Soong S.J. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
2. Cantley L.C. The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657
3. Chin L. Garraway L.A. Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era Genes Dev 20 2006 2149 2182
4. Clement S. Krause U. Desmedt F. The lipid phosphatase SHIP2 controls insulin sensitivity Nature 409 2001 92 97
5. Curtin J.A. Fridlyand J. Kageshita T. Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147
6. Dai D.L. Martinka M. Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases J Clin Oncol 23 2005 1473 1482
7. Dankort D. Curley D.P. Cartlidge R.A. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma Nat Genet 41 2009 544 552
8. Dhawan P. Singh A.B. Ellis D.L. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression Cancer Res 62 2002 7335 7342
9. Dull T. Zufferey R. Kelly M. A third-generation lentivirus vector with a conditional packaging system J Virol 72 1998 8463 8471
10. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562
11. Fedele C.G. Ooms L.M. Ho M. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers Proc Natl Acad Sci USA 107 2010 22231 22236
12. Ferron M. Vacher J. Characterization of the murine Inpp4b gene and identification of a novel isoform Gene 376 2006 152 161
13. Gewinner C. Wang Z.C. Richardson A. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling Cancer Cell 16 2009 115 125
14. Goel V.K. Lazar A.J. Warneke C.L. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma J Invest Dermatol 126 2006 154 160
15. Hodgson M.C. Shao L.J. Frolov A. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer Cancer Res 71 2011 572 582
16. Keniry M. Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy Oncogene 27 2008 5477 5485
17. Kim M. Gans J.D. Nogueira C. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene Cell 125 2006 1269 1281
18. Kudchadkar R.R. Smalley K.S. Glass L.F. Targeted therapy in melanoma Clin Dermatol 31 2013 200 208
19. Lin W.M. Baker A.C. Beroukhim R. Modeling genomic diversity and tumor dependency in malignant melanoma Cancer Res 68 2008 664 673
20. Madhunapantula S.V. Robertson G.P. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma Pigment Cell Melanoma Res 22 2009 400 419
21. Mikhail M. Velazquez E. Shapiro R. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation Clin Cancer Res 11 2005 5153 5157
22. Mirmohammadsadegh A. Marini A. Nambiar S. Epigenetic silencing of the PTEN gene in melanoma Cancer Res 66 2006 6546 6552
23. Nikolaou V.A. Stratigos A.J. Flaherty K.T. Melanoma: new insights and new therapies J Invest Dermatol 132 2012 854 863
24. Nogueira C. Kim K.H. Sung H. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis Oncogene 29 2010 6222 6232
25. Norris F.A. Atkins R.C. Majerus P.W. The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family J Biol Chem 272 1997 23859 23864
26. Norris F.A. Auethavekiat V. Majerus P.W. The isolation and characterization of cDNA encoding human and rat brain inositol polyphosphate 4-phosphatase J Biol Chem 270 1995 16128 16133
27. Posch C. Moslehi H. Feeney L. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo Proc Natl Acad Sci USA 110 2013 4015 4020
28. Ross M.E. Zhou X. Song G. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling Blood 102 2003 2951 2959
29. Sarbassov D.D. Guertin D.A. Ali S.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
30. Siegel R. Naishadham D. Jemal A. Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
31. Stahl J.M. Sharma A. Cheung M. Deregulated Akt3 activity promotes development of malignant melanoma Cancer Res 64 2004 7002 7010
32. Tsao H. Goel V. Wu H. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma J Invest Dermatol 122 2004 337 341
33. Tsao H. Zhang X. Fowlkes K. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines Cancer Res 60 2000 1800 1804
34. Villanueva J. Vultur A. Lee J.T. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
35. Westbrook T.F. Martin E.S. Schlabach M.R. A genetic screen for candidate tumor suppressors identifies REST Cell 121 2005 837 848
36. Ye Y. Jin L. Wilmott J.S. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma Nat Commun 4 2013 1508